<?xml version="1.0" encoding="UTF-8"?>
<p id="para0036">As reported by WHO (13 December 2019), among 1,568 laboratory-confirmed A(H7N9) patients, 33 had HPAI A(H7N9) virus infection, including one patient from Taiwan (the case had visited Guangdong province), and others from Guangxi, Guangdong, Hunan, Shaanxi, Hebei, Henan, Fujian, Yunnan, and Inner Mongolia [
 <xref rid="bib0026" ref-type="bibr">26</xref>,
 <xref rid="bib0027" ref-type="bibr">27</xref>]. One study reported that clinical outcomes were similar between hospitalized HPAI and LPAI A(H7N9) patients, except that the time from hospitalization to discharge was longer for HPAI patients 
 <xref rid="bib0028" ref-type="bibr">[28]</xref>. In our study, all 12 patients enrolled from the 2016-17 5th epidemic wave lived in Jiangxi Province. Lu et al. reported that A(H7N9) viruses isolated from humans in Jiangxi province in the 5th epidemic wave belonged to clade C1, while the HPAI A(H7N9) virus clade likely emerged from clade C2 
 <xref rid="bib0029" ref-type="bibr">[29]</xref>. Therefore, we do not believe that any of the 5th epidemic wave patients included in our study had HPAI A(H7N9) virus infection.
</p>
